Astria Therapeutics, Inc. (ATXS)

In the past six months, Astria Therapeutics' stock (ATXS) has trended up by 138.77%. A major event was the announcement on October 14, 2025, that BioCryst Pharmaceuticals, Inc. agreed to acquire Astria Therapeutics for approximately $700 million in a cash and stock transaction. Astria reported its Q2 2025 earnings on August 12, 2025, posting an EPS of -$0.57, which beat analysts' expectations. Astria initiated the Phase 3 ORBIT-EXPANSE Long-Term Trial of Navenibart on October 8, 2025. Following the acquisition announcement, Citizens downgraded Astria Therapeutics' stock rating from Market Outperform to Market Perform, and Oppenheimer downgraded it from Outperform to Perform, while H.C. Wainwright reiterated its Buy rating.

The provided search results do not contain specific information regarding demand seasonality for Astria Therapeutics, Inc.'s products and services. As a clinical-stage biopharmaceutical company, its revenue currently stems from capital raises and interest income on cash reserves, rather than product sales. Therefore, traditional demand seasonality for products is not applicable at this stage of the company's development.

Astria Therapeutics, Inc. (ATXS) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for rare allergic and immunological diseases. The company's lead product candidate is navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, currently in Phase 3 clinical trials for hereditary angioedema (HAE). Astria Therapeutics is also developing STAR-0310, a monoclonal antibody OX40 antagonist, which is in clinical development for the treatment of atopic dermatitis (AD).

Astria Therapeutics, Inc. is headquartered in Boston, Massachusetts, United States, and focuses on therapeutics for allergic and immunological diseases in the United States. Its clinical trials, including the ALPHA-ORBIT Phase 3 trial for navenibart, are global, and it has a licensing deal for navenibart in Japan.

Astria Therapeutics' brand reputation is tied to the progress of its drug candidates, particularly navenibart (STAR-0215). In March 2024, the company shared positive initial proof-of-concept results from the ALPHA-STAR Phase 1b/2 trial of STAR-0215 for HAE. In December 2024, positive final top-line results from the ALPHA-STAR trial further reinforced the efficacy and safety profile of navenibart. In February 2025, Astria initiated the ALPHA-ORBIT pivotal Phase 3 trial for navenibart. The announcement of BioCryst Pharmaceuticals' acquisition of Astria Therapeutics in October 2025 boosted confidence in Astria's pipeline.

Astria Therapeutics, Inc. (US:ATXS) has 265 institutional owners and shareholders holding a total of 62,021,359 shares. Major institutional owners include Perceptive Advisors Llc, Fmr Llc, Vestal Point Capital, LP, Fcpm Iii Services B.v., BlackRock, Inc., Fairmount Funds Management LLC, Millennium Management Llc, TCG Crossover Management, LLC, Vanguard Group Inc, VR Adviser, LLC, RA Capital Management, L.P., ForGrowth III PA B.V., and Venrock Healthcare Capital Partners III, L.P.